BEAM-101
Phase 2Biologic
Beam TherapeuticsBEAM-101 is one of 51 biologic programs targeting Sickle Cell Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Fludara
SanofiPhase 2
Cellcept
RochePhase 2
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
PIASKY
RochePhase 3
Tepadina
Jazz PharmaceuticalsPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Rituxan
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BEAM-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company